Health Care & Life Sciences » Pharmaceuticals | Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Adamas Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
SPDR S&P Biotech ETF
1,958,198
7.2%
5,037
0.77%
09/06/2018
Invesco Small Cap Growth Fund
902,799
3.32%
142,370
0.63%
06/29/2018
Delaware Small Cap Core Fund
876,100
3.22%
92,500
0.55%
05/31/2018
Rhenman & Partners Fund - Healthcare Equity L/S
692,913
2.54%
324,747
1.12%
12/31/2017
Vanguard Total Stock Market Index Fund
546,660
2%
0
0%
07/31/2018
JNL/Invesco Small Cap Growth Fund
499,433
1.84%
-9,436
0.53%
03/31/2018
Fidelity Select Biotechnology Portfolio
492,169
1.81%
-107,200
0.12%
07/31/2018
iShares Russell 2000 ETF
459,701
1.69%
-246
0.02%
09/06/2018
Janus Global Life Sciences Fund
409,480
1.51%
-1,545
0.23%
06/30/2018
351,320
1.29%
0
2.56%
05/31/2018

About Adamas Pharmaceuticals

View Profile
Address
1900 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.adamaspharma.com
Updated 07/08/2019
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.